![]() (Nasdaq: GILD) and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Gilead Investor Presentation, Gilead to Acquire Kite: Creating a Global Leader. & SANTA MONICA, Calif.- (BUSINESS WIRE)- Gilead Sciences, Inc. He is certified by the American Board of Urology and the American Association of Genitourinary Surgeons. Amanda Micklus, Maureen Riordan, and Theresa Suprenant, Pharmaceutical/. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy and cancer vaccines. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. Prior to joining UCLA, Arie was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Arie is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He is also co-Founder and Senior Managing Director of Vida Ventures, a life science venture group with offices in Boston and Los Angeles. He currently serves as Chairman of Two River Group, UroGen Pharma, and Bellco Capital, and as co-Chairman of Breakthrough Properties. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. BACK INTO MAIN MENU Company Statements Kite’s Yescarta First CAR T-cell Therapy to Receive Health Hong-kong Authorization for Use as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma Christi Shadow toward Depart Gilead and Kite Governance Finalize of Q1 Kite’s Yescarta is First Auto T-Cell Remedy Recommended for Run Use in Blighty, United Kingdom Kite Expands Cell Therapy. ![]() ![]() Arie has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. A visionary entrepreneur, Arie founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. Kite Pharma released interim results for its ZUMA-1 clinical trial and presented data at the annual American Society for Hematology (ASH). He is also Executive Chairman and Co-Founder of Allogene Therapeutics, a clinical stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. (Nasdaq:KITE) presented updates on its advancing pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates and KTE-C19 launch readiness at its Investor Day in New York on October 18, 2016. Arie Belldegrun, M.D., is the chair of the board of Kronos Bio.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |